GT Biopharma, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
GTBP$4.42-2.6%Stored close · as of Nov 6, 2026
Contents
Item 1. Financial Statements
| Condensed Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025 | 3 | |
| Condensed Statements of Operations for the three and six months ended June 30, 2026 and 2025 (Unaudited) | 4 | |
| Condensed Statements of Stockholders’ Equity (Deficit) for the three and six months ended June 30, 2026 and 2025 (Unaudited) | 5 | |
| Condensed Statements of Cash Flows for the six months ended June 30, 2026 and 2025 (Unaudited) | 7 | |
| Notes to Unaudited Condensed Financial Statements | 8 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 19 |
|---|---|---|
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 25 |
| Item 4. | Controls and Procedures | 25 |
| PART II OTHER INFORMATION | ||
| Item 1. | Legal Proceedings | 27 |
| Item 1A. | Risk Factors | 27 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 27 |
| Item 3. | Defaults Upon Senior Securities | 27 |
| Item 4. | Mine Safety Disclosures | 27 |
| Item 5. | Other Information | 27 |
| Item 6. | Exhibits | 28 |
| SIGNATURES | 29 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.